Good morning. Elizabeth Cooney here in Boston, filling in for Ed Silverman while he’s reporting from the J.P. Morgan Healthcare Conference in San Francisco. You can follow STAT’s team coverage of the gathering in the Readout @ JPM. Here’s what we’re watching in biopharma today:

Allergan (AGN) CEO Brent Saunders, who famously declared in 2016 that his company would keep a “social contract” by ensuring price hikes — after rebates and discounts — would remain below double digits and not exceed inflation, told STAT the company is staying true to its promise, with some hikes at 9.5 percent, some at zero, and an average of 3.5 percent across its portfolio. “I think we absolutely lived up to well beyond the spirit and heart of our social contract, because our net prices are below the cost of inflation, which means, economically, they’re in decline.”

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • “Well take this, Secretary Azzar, we don’t report to you anymore.” That at least is my read – “Eli Lilly (LLY) won’t put the price of its prescription drugs in television ads, as the Trump administration has called for …”
    And as of 9:27 EDT today, the link only shows the label for Trulicity, sans the Lily promised pricing data – but it is early yet at JPM so who knows?

Comments are closed.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy